11.4 Non-Prescription Products: OTC Labeling, Repackaging, Exempt Narcotics & Restricted Distribution
Key Takeaways
- The Drug Facts label required by 21 C.F.R. § 201.66 must present Active ingredients, Purpose, Uses, Warnings, Directions, Other information, and Inactive ingredients in that fixed order, with a Questions? contact.
- Ala. Admin. Code r. 680-X-2-.04(2) requires every Alabama community pharmacy to keep an exempt narcotic register on hand, the bound record for Schedule V products sold without a prescription.
- Under 21 C.F.R. § 1306.26 a Schedule V exempt narcotic may be sold without a prescription only by a pharmacist, to a purchaser at least 18 years old who presents identification, limited to 240 mL or 48 dosage units of an opium-containing preparation and 120 mL or 24 dosage units of any other controlled substance in a 48-hour period.
- Syringes may be sold in Alabama without a prescription, and the pharmacist retains professional discretion to decline a sale.
- A Risk Evaluation and Mitigation Strategy with Elements To Assure Safe Use can require prescriber certification, pharmacy certification, patient enrollment, and documentation of safe-use conditions before dispensing; a pharmacy that is not certified cannot lawfully dispense the product regardless of the prescription’s validity.
11.4 Non-Prescription Products: OTC Labeling, Repackaging, Exempt Narcotics & Restricted Distribution
[!IMPORTANT] Core Exam Concept: The MPJE Competency Statements devote an entire sub-area to non-prescription products — their dispensing or administration, their labeling, their packaging and repackaging, and the sale of restricted non-prescription drugs. Candidates who study only prescription law leave that ground uncovered. A second, related area asks about requirements for drug uses, limitations, or restrictions, which is where REMS programs live. This section closes both.
1. The OTC Monograph System and the Drug Facts Label
A drug may be sold over the counter when its conditions of use are recognized as generally recognized as safe and effective (GRASE) — historically through an OTC monograph, and since the CARES Act of 2020 through the reformed OTC monograph order process — or when FDA approves an Rx-to-OTC switch through an NDA.
21 C.F.R. § 201.66 prescribes the standardized Drug Facts panel. The order is fixed and is itself examinable:
+-----------------------------------------------------------------------------------------+
| DRUG FACTS PANEL -- MANDATORY ORDER |
+-----------------------------------------------------------------------------------------+
| 1. Active ingredient(s) ... with the amount per dosage unit |
| 2. Purpose ... the general pharmacologic category |
| 3. Uses ... the indications |
| 4. Warnings ... in a fixed internal order: Do not use / Ask a doctor / |
| Ask a doctor or pharmacist before use / When using this |
| product / Stop use and ask a doctor / pregnancy-nursing / |
| Keep out of reach of children |
| 5. Directions ... dosage by age group |
| 6. Other information ... e.g., storage, sodium content |
| 7. Inactive ingredients ... alphabetical |
| 8. Questions or comments?... a telephone number for the responsible firm |
+-----------------------------------------------------------------------------------------+
- "Keep out of reach of children" is not optional, and neither is the accidental-overdose instruction to contact a poison control center — which pairs with the requirement that the poison control telephone number be posted in the prescription department.
- Tamper-Evident Packaging (21 C.F.R. § 211.132): OTC drug products for retail sale must use tamper-evident packaging, and the labeling must describe the safety feature so a consumer can recognize tampering. Two-piece hard gelatin capsules require two tamper-evident features unless sealed.
2. Repackaging and Labeling Non-Prescription Products
When a pharmacy repackages an OTC product — breaking a bulk container into smaller units for sale, or preparing a unit-dose for an institution — it takes on manufacturer-style labeling duties.
| Situation | Required Labeling |
|---|---|
| OTC sold in the manufacturer's container | The manufacturer's Drug Facts panel suffices |
| OTC repackaged by the pharmacy for retail sale | Name and address of the repackager, product name, active ingredients and amounts, quantity, lot number, expiration date, and the required warnings |
| OTC dispensed against a prescription | The product becomes a dispensed prescription and takes the prescription label required by Ala. Admin. Code r. 680-X-2-.13 — pharmacy name and address, prescriber's directions for use, drug name as dispensed, and strength per dosage unit |
| OTC repackaged as institutional unit-dose | Drug name, strength, lot number, and expiration date legible on each individual unit |
[!NOTE] The insurance question is a labeling question. Patients frequently ask for a prescription for an OTC product so a plan will pay. Once the pharmacist dispenses it against that prescription, the container carries a prescription label under r. 680-X-2-.13, is entered in the prescription record system under r. 680-X-2-.15, and is subject to the counseling offer under r. 680-X-2-.21. It is no longer an over-the-counter transaction.
3. Restricted Non-Prescription Sales
Schedule V Exempt Narcotics (21 C.F.R. § 1306.26)
A controlled substance in Schedule V that is not a prescription drug may be sold at retail without a prescription only if all of the following hold:
- The sale is made by a pharmacist — the pharmacist may delegate the money-and-bag mechanics to a non-pharmacist after making the actual sale, but the professional decision cannot be delegated;
- Not more than 240 mL (8 ounces) or 48 dosage units of an opium-containing substance, and not more than 120 mL (4 ounces) or 24 dosage units of any other controlled substance, are sold to the same purchaser in any 48-hour period;
- The purchaser is at least 18 years of age;
- The pharmacist requires suitable identification from a purchaser not known to the pharmacist; and
- A bound record book is maintained containing the purchaser's name and address, the name and quantity of the substance, the date, and the name or initials of the dispensing pharmacist. That book must be kept for two years.
Alabama supplies the register expressly: under Ala. Admin. Code r. 680-X-2-.04(2), "community pharmacies shall have on hand an exempt narcotic register." Its absence is an independent inspection finding, separate from any question about whether a sale occurred.
Ephedrine and Pseudoephedrine
Covered in detail in section 11.3. In summary, Alabama restricts sales to pharmacies licensed by the Board, requires the product to be stored behind the pharmacy counter, limits a purchaser to 3.6 grams per calendar day and 7.5 grams per 30 days — stricter than the federal 9-gram monthly figure — requires the purchaser to be at least 18 with a valid government-issued ID, and requires electronic submission to NPLEx before the sale.
Syringes and Needles
The Alabama Board of Pharmacy's published position is that syringes may be sold in Alabama without a prescription. Unlike states with paraphernalia statutes or age restrictions on syringe sales, Alabama permits the sale, and the pharmacist retains professional discretion to decline a sale they judge inappropriate. That discretion is the practice point: the absence of a legal bar is not a duty to sell.
Naloxone
Available through the statewide standing order discussed in section 4.2, which functions as a prescription rather than as an over-the-counter sale for the products it covers, even though FDA has since approved OTC naloxone nasal spray.
4. Restricted Distribution of Prescription Drugs: REMS
The blueprint's "requirements for drug uses, limitations, or restrictions" reaches the FDA's Risk Evaluation and Mitigation Strategy authority under the Food and Drug Administration Amendments Act of 2007.
| REMS Component | What It Means | Pharmacy Consequence |
|---|---|---|
| Medication Guide / Patient Package Insert | Written information the patient must receive | Must be distributed each time the drug is dispensed |
| Communication Plan | Directed at healthcare providers | No pharmacy gate, but affects counseling |
| Elements To Assure Safe Use (ETASU) | The restrictive tier | May require prescriber certification, pharmacy certification, patient enrollment/monitoring, dispensing only in certain settings, or documentation of safe-use conditions before each dispense |
| Implementation System | Sponsor monitoring of ETASU compliance | Pharmacy audits and data submission |
[!CAUTION] A valid prescription is not sufficient when ETASU applies. If the pharmacy is not certified in the program, or the prescriber is not certified, or the patient is not enrolled and current on required monitoring, the pharmacy cannot lawfully dispense — no matter how facially perfect the prescription is. Familiar ETASU programs include clozapine (absolute neutrophil count monitoring), isotretinoin (iPLEDGE) (pregnancy testing and dual contraception), thalidomide and lenalidomide, sodium oxybate, and mifepristone. The correct pharmacist action when a REMS requirement is unmet is to hold the prescription and resolve the deficiency, not to dispense and document.
Two related restriction mechanisms round out the topic:
- Medication Guides (21 C.F.R. Part 208) exist independently of REMS for drug classes with serious risks, and must be provided at each dispensing.
- Patient Package Inserts (21 C.F.R. § 310.501, § 310.515) are mandatory for oral contraceptives and estrogen-containing products, and must be dispensed with each fill including refills.
A 17-year-old presents at an Alabama community pharmacy counter asking to buy a Schedule V antitussive containing codeine that is not a prescription drug in Alabama, along with a box of insulin syringes. The pharmacist knows the customer. How should the pharmacist proceed?
A patient brings a prescription for a REMS drug with Elements To Assure Safe Use. The prescription is complete, the prescriber is certified in the program, and the patient is enrolled and current on required laboratory monitoring, but the pharmacy itself has never completed REMS certification. What is the pharmacist’s correct course of action?
An Alabama community pharmacy buys a 1,000-count bulk bottle of an over-the-counter analgesic and repackages it into 100-count bottles for sale on the retail shelf. Which labeling obligation attaches to the repackaged bottles?